We are a research and innovation driven, ISO 13485:2016, ISO 9001:2015 and OHSAS 18001:2007 certified company, established in 1999 at Navi Mumbai, Maharashtra, India. We have operations in Germany, USA and will soon establish presence in South Korea. Our research, development and production-related activities encompass a whole range of native, recombinant and cell-derived antigens; and monoclonal antibodies. Highest standards of quality and unwavering commitment towards healthcare innovation have enabled us to capture some of the biggest market segments for various biomarker antigens and antibodies.
More recently, our company has ventured into the preclinical drug discovery space, using the unique technology of induced pluripotent stem cells (iPSCs). Our core objectives in this field are: Bio-banking of human clinical samples (from cancer patients or age and gender matched controls), Use of iPSCs and its derivatives (i.e. wild type and mutated iPSCs) for drug discovery and disease modeling, Use of iPSC derived differentiated lineages such as cardiomyocytes, hepatocytes for drug toxicology, and Regenerative medicine and therapy.